Luke Evnin, PhD
Dr. Evnin is the chairman of the board and a co-founder of Harpoon Therapeutics; he is also the co-founder and managing director of MPM Capital. MPM Capital is known for its leadership role in building companies such as Biomarin, CoStim Pharmaceuticals (acquired by Novartis), Epizyme, Idenix (acquired by Merck) Pacira, Pharmasset (acquired by Gilead) and Radius. Dr. Evnin was the lead investor and has served on the boards of several of MPM’s most successful investments including CoStim Pharmaceuticals, Idun Pharmaceuticals, and Pacira. Prior to MPM, Dr. Evnin was a venture capitalist at Accel Partners where he focused on emerging healthcare companies. He received his AB in molecular biology from Princeton University and received his PhD in Biochemistry from the University of California, San Francisco. He is the chairman of the Scleroderma Research Foundation, as well as an advisor for the Lewis-Sigler Institute for Quantitative Genomics at Princeton, for QB3 at UCSF, and for Mission Bay Capital at UCSF.